This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

ImmunoCellular Therapeutics’ Data From Phase I Trial Of ICT-107 Accepted For Publication In Prestigious Medical Journal, Cancer Immunology, Immunotherapy

Stocks in this article: IMUC

ImmunoCellular Therapeutics (NYSE MKT: IMUC) announced today that clinical data from its Phase I trial of ICT-107 was accepted for publication, and is currently in the online edition of the prestigious medical journal Cancer Immunology, Immunotherapy ( http://www.springerlink.com/content/n0018574g9m4v587/fulltext.pdf ). In the publication, the data showed that the expression of four ICT-107 targeted antigens in the pre-vaccine tumors correlated with longer overall survival (OS) and progression free survival (PFS) in newly diagnosed glioblastoma multiforme (GBM) patients. Median PFS in newly diagnosed GBM patients was 16.9 months and median OS was 38.4 months.

Tumors from post-vaccine resections in five patients showed a decrease in or loss of the cancer stem cell associated antigen CD133 relative to their pre-vaccine counterparts, which may be promising because previous studies have consistently shown increased expression of CD133 in recurrent tumors. The idea of cancer stem cell therapeutics has received increasing attention, including through publications noting IMUC’s progress in the clinic with its ICT-107 vaccine targeting antigens associated with cancer stem cells and articles in the recent issues of  Nature and Science noting the significance of cancer stem cells to tumor growth.

In the Phase I study to evaluate the safety and immune responses to ICT-107, 21 patients were enrolled, including 17 newly diagnosed (16 evaluable as one did not receive any treatment) and three recurrent GBM patients and one with brainstem glioma. Tumor associated antigen expression analysis showed all patients had at least three of the antigens and 75% had all six of the antigens targeted by ICT-107. At a median follow-up of 40.1 months, six of the newly diagnosed patients showed no evidence of tumor recurrence. “We are extremely pleased that our clinical results were accepted for publication,” said Manish Singh, Ph.D., ImmunoCellular’s president and CEO. “The publication of the data in yet another respected medium, as well as the recent  Nature articles detailing the importance of cancer stem cells to tumor growth, validate the potential of our clinical programs for the treatment of patients with either newly diagnosed or recurrent GBM.”

About ImmunoCellular Therapeutics, Ltd.

ImmunoCellular Therapeutics ( IMUC) is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. The Company is currently conducting a Phase II trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor associated antigens for newly diagnosed glioblastoma. To learn more about IMUC, please visit www.imuc.com

Forward-Looking Statements

This press release contains certain forward-looking statements that are subject to a number of risks and uncertainties, including the risk that the prior safety and efficacy results for ICT-107 will not be confirmed in current or any subsequent trials of that product candidate in statistically significant larger patient populations. . Additional risks and uncertainties are described in IMUC’s most recently filed SEC documents, such as its most recent annual report on Form 10-K, all quarterly reports on Form 10-Q and any current reports on Form 8-K. IMUC undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.



1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,603.76 +204.09 1.24%
S&P 500 1,940.06 +36.05 1.89%
NASDAQ 4,414.1150 +98.0410 2.27%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs